Biocon Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve To approve and take on record the un-audited standalone and consolidated financial results of the Company for the quarter and half year ended on September 30, 2026

Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 E: co.secretary@biocon.com www.biocon.com BIO/SECL/TG/2026-27/76 October 26, 2026 To, To, The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of Corporate Services Corporate Communication Department Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Mumbai – 400 001 Mumbai – 400 051 Scrip Code – 532523 Scrip Symbol – Biocon Dear Sir/Madam, Subject: Intimation for the Board Meeting and Earnings Conference Call for Analysts and Investors Pursuant to Regulation 29(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, November 04, 2026, inter alia, to approve and take on record the un-audited standalone and consolidated financial results of the Company for the quarter and half year ended on September 30, 2026, amongst other matters. Pursuant to the Code of Conduct for Prevention of Insider Trading of the Company read with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in securities of the Company has been closed from Thursday, October 01, 2026 to Friday, November 06, 2026 (both days inclusive). Accordingly, the trading window will open on Saturday, November 07, 2026. The Company will organize an Earnings Conference Call for Analysts and Investors on Wednesday, November 04, 2026. The details of the same are enclosed herewith. The above-mentioned information will also be available on website of the Company at www.biocon.com. Request you to take the above intimation on record. Thanking you, For Biocon Limited Rajesh U. Shanoy Company Secretary and Compliance Officer M. No.: ACS 16328 20th K.M. Hosur Road, Electronics City, Bengaluru 560 100 Oct 26, 2026 Biocon Limited Q2 FY 2026-27 Earnings Conference Call At 16:00 hrs. IST on Nov 4th, 2026 The management team of Biocon Limited (BSE code: 532523, NSE ID: BIOCON) will organize a conference call for Analysts and Investors following the announcement of financial results for the quarter ended Sep 30th, 2026. The call will be conducted over Zoom. Conference Call Details Date Wednesday, Nov 4, 2026 Time 16:00 hrs IST Registration Link Click here • Audio recording will be made available before the next trading day or within 24 hrs from the end of the call, whichever is earlier Recording • Video recording will be made available within 48 hrs from the end of the call • Access the recordings on the Company website (Biocon > Investors > Financial Information > Earnings Call Recordings) Will be made available within 5 working days of the conclusion of the call on the Conference Call Transcript Company website (Biocon > Investors > Financial Information > Earnings Call Transcripts) Note: Participants are requested to join 10 minutes before the scheduled start time of the call. For further information please contact: Prashant Nair Investor Relations – Biocon Limited P: +91 6775 1714/ +91 98200 95476 E: prashant.nair@biocon.com Safe Harbor: Certain statements that may be made in the conference call may be forward-looking based on management's current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India and overseas, and changes in the foreign exchange control regulations in India. Neither Biocon, nor our directors, nor any of our subsidiaries/associates assume any obligation to update any forward-looking statement contained in the conference call.